![American Society of Clinical Oncology American Society of Clinical Oncology](https://54d4f314-8f94-415c-acb7-fd0a6332f070.s3.amazonaws.com/403/403__asco-logo-lg__274272709.png?X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIAU2BE4PNFKE2WZV7V%2F20240908%2Fus-east-1%2Fs3%2Faws4_request&X-Amz-Date=20240908T003827Z&X-Amz-SignedHeaders=host&X-Amz-Expires=86400&X-Amz-Signature=282ee7f73f20a290680b1ce4f68b0e950989390c88ac8aabfae013a379f0693d)
Appropriate Systemic Therapy Dosing for Obese Adult Patients with Cancer
Publication Date: April 25, 2021
Key Points
Key Points
- The Panel continues to recommend that full, weight-based cytotoxic chemotherapy doses be used to treat obese adults with cancer.
- The Panel also recommends that full, approved doses of immunotherapy and targeted therapies be offered to obese adults with cancer.
- In the event of toxicity, the consensus of the Panel is that dose modifications of systemic antineoplastic therapies should be handled similarly for obese and non-obese patients.
Treatment
Treatment
...ht-based dosing of cytotoxic chemotherapy shou...
...el recommends limiting fixed dosing of chemotherap...
...ed prescribing information for checkpoi...
...prescribing information for targeted therapies s...
If an obese patient experiences hig...
...anel recommends that BSA be calculated using a...